Senazodan
Alternative Names: MCI 154Latest Information Update: 27 May 2010
At a glance
- Originator Mitsubishi Chemical
- Developer Mitsubishi Chemical; Mitsubishi Tanabe Pharma Corporation
- Class Cardiotonics
- Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute heart failure
Most Recent Events
- 27 May 2010 Discontinued - Phase-II for Acute heart failure in Japan (PO)
- 01 Oct 2007 Mitsubishi Pharma Corporation has merged with Tanabe Seiyaku to form Mitsubishi Tanabe Pharma Corporation
- 20 Mar 2006 Senazodan is available for licensing worldwide(http://www.micusa.com)